About the Company
savara pharmaceuticals is an emerging specialty pharmaceutical company developing innovative pulmonary drugs for the treatment of serious and life-threatening conditions. the company’s lead product, aerovanc is the first dry powder inhaled antibiotic for the treatment of methicillin-resistant staphylococcus aureus (mrsa) infection in patients with cystic fibrosis (cf). for more information, please see savara’s website at www.savarapharma.com or www.aerovanc.com
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $SVRA News
Savara Reports Fourth Quarter/Year-End 2023 Financial Results and Provides Business Update
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, ...
Savara Inc. to Participate in Prominent Healthcare Conferences, Casting Spotlight on Future Plans
LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA), a leading biopharmaceutical company, recently announced its participation in two pivotal investor healthcare conferences in February 2024. The Bucks ...
Savara Inc. Reports Increased Expenses, Anticipates Positive Data from IMPALA-2 Trial
LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA), a clinical-stage biopharmaceutical company, recently reported an increase in both research and development (R&D) and general administrative expenses for the ...
Savara to Present at the Barclays 26th Annual Global Healthcare Conference
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced ...
Optimistic Buy Rating for Savara on Molgramostim’s Market Potential and Strong Financials
Analyst Jonathan Wolleben of JMP Securities reiterated a Buy rating on Savara (SVRA – Research Report), with a price target of $8.00.
Buy Rating Affirmed: Anticipating IMPALA-2 Trial Success and aPAP Treatment Breakthrough with Molgramostim
Andrew Fein, an analyst from H.C. Wainwright, reiterated the Buy rating on Savara (SVRA – Research Report). The associated price target ...
Rick Yang's Net Worth
Inc., Savara Inc, and Korro Bio, Inc.. Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and ...
Savara Inc (YB4P.SG)
*Close price adjusted for splits.**Close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...
Savara Inc. (SVRA)
*Close price adjusted for splits.**Close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...
Savara: Why Sauti Sol had to take a break from each other
Delvin Savara Mudigi, one of Sauti Sol, has clarified that they have not disbanded the band, which has been a significant ...
Loading the latest forecasts...